Quarterly Result23 May 2025, 08:22 pm
Glenmark Pharma Reports Q4 & FY25 Financial Results: India Business Grows by 31.9%, Europe by 17.6%, and RoW by 1.7%
AI Summary
Glenmark Pharmaceuticals Ltd. has announced its financial results for Q4FY25 and FY25 ended March 31, 2025. The company's India business grew by 31.9%, Europe by 17.6%, and the rest of the world (RoW) by 1.7%. The total consolidated revenue for Q4FY25 was Rs. 32,562 Mn, a 6.3% YoY increase. The total consolidated revenue for FY25 was Rs. 1,33,217 Mn, a 12.8% YoY increase. Glenmark assumed leadership positions in its key therapeutic areas in India and launched RYALTRIS® in more than 10 markets in FY25. The company's formulation business is spread across Branded, Generics, and OTC segments in the therapy areas of Dermatology, Respiratory and Oncology.
Key Highlights
- India business grew by 31.9% to Rs. 44,845 Mn
- Europe business grew by 17.6% to Rs. 28,463 Mn
- RoW business grew by 1.7% to Rs. 28,138 Mn
- Adjusted Profit After Tax (PAT)” of Rs. 13,894 Mn with Adjusted PAT margin” of 10.4%
- Glenmark assumed leadership position in its key therapeutic areas in India